Tag: Ocrelizumab

Higher-dosed ocrelizumab associated with less disability accrual

Presented By
Dr Robert Bermel, Cleveland Clinic, OH, USA
Trial
Phase 3, OPERA
Conference
ACTRIMS 2025
Type
News article

28 March 2025 11:21

Ocrelizumab significantly reduces new/enlarging cortical lesions

Presented By
Prof. Michael Dwyer, University at Buffalo, NY, USA
Trial
Phase 3, ORATORIO
Conference
ACTRIMS 2025
Type
News article

28 March 2025 11:19

Meet the Trialist: Dr Jiwon Oh

Expert
Dr Jiwon Oh, St Michael’s Hospital, University of Toronto, Canada
Conference
ACTRIMS 2025

5 March 2025 10:59

B cell-tailored dosing of ocrelizumab shows good results

Presented By
Ms Laura Hogenboom, Amsterdam University Medical Center, the Netherlands
Trial
BLOOMS
Conference
ECTRIMS 2024
Type
Peer-reviewed article

18 November 2024 12:28

Risk associated with discontinuing therapy depends on specific drug

Conference
ECTRIMS 2024
Type
Peer-reviewed article

18 November 2024 12:26

Transfer of ocrelizumab into breastmilk is negligible

Presented By
Dr Riley Bove, University of California San Francisco, CA, USA
Trial
Phase 4, SOPRANINO
Conference
ECTRIMS 2024
Type
Peer-reviewed article

18 November 2024 12:03

Early initiation of highly active treatment associated with a lower risk of SPMS

Presented By
Dr Christine Lebrun-Frenay, CHU de Nice, France
Trial
SPAM
Conference
MSMilan 2023
Type
Peer-reviewed article

4 December 2023 11:10

Ocrelizumab more effective than interferon/glatiramer acetate in older MS patients

Presented By
Dr Yi Chao Foong, Monash University, Australia
Conference
MSMilan 2023
Type
Peer-reviewed article

4 December 2023 11:09

Real-world data supports ocrelizumab prior to conception

Presented By
Dr Wei Yeh, Alfred Health and Monash University, Australia
Conference
MSMilan 2023
Type
Peer-reviewed article

4 December 2023 11:07

Positive 4-year efficacy and safety data of ocrelizumab in early MS

Trial
Phase 3, ENSEMBLE
Conference
AAN 2023
Type
Peer-reviewed article

26 June 2023 20:36

Ocrelizumab and fingolimod increase the risk of COVID-19 and of worse outcomes

Presented By
Dr Nikos Evangelou, Nottingham University Hospital, UK
Conference
ECTRIMS 2022
Type
Peer-reviewed article

20 December 2022 11:46

Pregnancy and infant outcomes in women receiving ocrelizumab

Presented By
Prof. Celia Oreja-Guevara, University Hospital San Carlos, Spain
Conference
ECTRIMS 2022
Type
Peer-reviewed article

20 December 2022 10:29

New safety data of anti-CD20 mAbs around pregnancy

Presented By
Dr Carolin Schwake, Ruhr-University Bochum, Germany
Conference
ECTRIMS 2022
Type
Peer-reviewed article

20 December 2022 10:24

Comparing real-world effectiveness of DMTs

Presented By
Prof. Marcello Moccia, University College London, UK
Conference
ECTRIMS 2022
Type
Peer-reviewed article

20 December 2022 09:05

Study fails to show non-inferiority of rituximab to ocrelizumab

Presented By
Dr Izanne Roos, University of Melbourne, Australia
Conference
ECTRIMS 2022
Type
Peer-reviewed article

20 December 2022 08:55

ECTRIMS 2022 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
ECTRIMS 2022

15 November 2022 00:08

Charcot Award 2021: Progressive MS, a personal perspective

Presented By
Prof. Alan J. Thompson, University College London, UK
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 15:48

Ocrelizumab shows long-term benefits in primary progressive MS

Presented By
Prof. Jerry S. Wolinsky, University of Texas Health Science Center at Houston, TX, USA
Trial
Phase 3, ORATORIO
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 15:39

ECTRIMS/EAN Clinical Guidelines on MS treatment: an update

Presented By
Prof. Xavier Montalban, Vall d’Hebron University Hospital, Spain
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 14:37

Long-term suppression of MRI disease activity with ocrelizumab

Presented By
Dr Douglas Arnold, McGill University, Canada
Trial
Phase 3, OPERA I/II, ORATORIO
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 14:30

Elezanumab did not outperform placebo in progressive and relapsing MS

Presented By
Prof. Bruce Cree, University of California, CA, USA
Trial
Phase 2, RADIUS-R, RADIUS-P
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 14:10

MS patients at risk of hampered immune response after vaccination

Presented By
Prof. Maria Pia Sormani, University of Genoa, Italy
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 10:49

Anti-CD20 antibodies associated with worse COVID-19 outcomes

Presented By
Dr Steve Simpson-Yap, University of Melbourne, Australia
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 10:41

ECTRIMS-EAN consensus on vaccination in MS patients

Presented By
Dr Mauricio Farez, Fundacion FLENI, Argentina
Conference
ECTRIMS 2021
Type
Peer-reviewed article

9 December 2021 10:35

MS therapies influence COVID-19 severity

Conference
AAN 2021
Type
Peer-reviewed article

16 June 2021 11:42

Do anti-CD20 DMTs cause worse COVID-19 outcomes in MS?

Presented By
Dr Steve Simpson-Yap, Melbourne School of Population and Global Health, Australia
Journal
Physician’s Weekly
Conference
MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting

15 April 2021 16:27

Real-world efficacy of ocrelizumab in MS patients

Presented By
Julius Eggebrecht, Roche Pharma, Germany
Trial
Phase 4, CONFIDENCE
Conference
ECF 2020
Type
News article

16 December 2020 10:24

Risk of COVID-19 not increased in MS patients

Conference
MS Virtual 2020
Type
Peer-reviewed article

25 November 2020 17:10

Anti-CD20 DMTs associated with worse COVID-19 outcomes

Conference
MS Virtual 2020
Type
Peer-reviewed article

25 November 2020 17:09

Management of progressive MS with approved DMT

Presented By
Prof. Xavier Montalban, Vall d'Hebron University Hospital, Spain
Trial
ASCEND, MS-SMART
Conference
MS Virtual 2020
Type
Peer-reviewed article

25 November 2020 17:01

Less thalamic atrophy in patients initiating ocrelizumab earlier

Conference
MS Virtual
Type
Peer-reviewed article

25 November 2020 16:59

High NEDA rates after 2 years of ocrelizumab

Presented By
Prof. Patrick Vermersch, University of Lille, France
Trial
Phase 3, CASTING
Conference
EAN 2020
Type
Peer-reviewed article

10 September 2020 12:25

Switching from natalizumab to moderate- versus high-efficacy DMT

Presented By
Dr Carrie M. Hersh, Cleveland Clinic Lerner College of Medicine, OH, USA
Conference
EAN 2020
Type
Peer-reviewed article

10 September 2020 12:17

Treatment escalation over induction therapy

Presented By
Dr Emmanuelle Waubant, University of California, San Francisco, USA
Conference
ECTRIMS 2019
Type
Peer-reviewed article

8 November 2019 22:40

Sustained reduction in disability progression with ocrelizumab

Presented By
Prof. Jerry Wolinsky, University of Texas, USA
Trial
Phase 3, ORATORIO
Conference
ECTRIMS 2019
Type
Peer-reviewed article

8 November 2019 19:32

Serum immunoglobulin levels and risk of serious infections

Presented By
Prof. Tobias Derfuss, University Hospital Basel, Switzerland
Conference
ECTRIMS 2019
Type
Peer-reviewed article

8 November 2019 19:23

Sequencing of high-efficacy disease-modifying treatments in MS

Trial
OCTAVE
Conference
AAN 2019
Type
Peer-reviewed article

30 July 2019 20:12

Biotin, ocrelizumab, and ibudilast in progressive MS

Expert
Dr Andrew Goodman, University of Rochester School of Medicine and Dentistry, USA
Trial
ORATORIO, Phase 3; SPRINT-MS, Phase 2; MS-SPI, Phase 3
Conference
AAN 2019
Type
Peer-reviewed article

30 July 2019 19:15
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com